DeepHealth Expands Breast Suite with FDA Clearances for Cardiovascular and Prior Exam Tools
Event summary
- DeepHealth received two FDA 510(k) clearances for new Breast Suite functionalities: Breast Arterial Calcification (BAC) Assessment and Prior Exam Integration into Mammo Dx.
- BAC Assessment identifies breast arterial calcifications, a potential early indicator of cardiovascular disease, with over 90% sensitivity and 88% specificity in clinical testing.
- Mammo Dx integrates prior exams to track lesions and improve cancer detection rates, reducing recalls.
- Both functionalities are now commercially available in the U.S. and will be deployed across RadNet imaging centers.
The big picture
DeepHealth's latest FDA clearances reinforce its position as a leader in AI-powered breast imaging, addressing critical gaps in cardiovascular risk assessment and cancer detection. The enhancements to Breast Suite align with the broader trend of integrating multi-modal data into diagnostic workflows, potentially setting a new standard for comprehensive patient care.
What we're watching
- Clinical Adoption
- How the integration of BAC Assessment and Mammo Dx will affect radiologist workflows and patient outcomes.
- Market Differentiation
- Whether DeepHealth can sustain its lead in breast imaging AI with these enhancements.
- Regulatory Compliance
- The pace at which additional FDA clearances for other DeepHealth products may be achieved.
Related topics